Some clinical studies are investigator-initiated trials (IITs). This type of clinical research is designed and led by a medical researcher or clinician. IITs often explore new uses for existing treatments, compare different treatments or investigate rare diseases. Nationwide Children’s is passionate about making a difference in the lives of children not only here in Columbus, Ohio, but across the country and around the world.
Nationwide Children’s acknowledges the significant role research has in improving child health, with a focus on translating discoveries into best outcomes for all kids. That’s why Nationwide Children’s is a national leader in cancer research. In addition to participating in national and international cancer studies, Nationwide Children’s supports investigator-initiated cancer clinical trials. IITs provide physician researchers new opportunities to study and identify new ways to use existing treatments. And for the rare diseases and cancers that affect children, this cutting-edge research often provides the next option for families who need it most.
In this research study, we want to find out if the study drug Lutathera, an IV infusion drug, is effective in treating different kinds of brain cancer.
Help researchers learn more about the effects of a study drug on children with brain tumors.
The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
The study aims to analyze the genes in brain tumors from kids, teens, and young adults who have just been diagnosed with a severe type of brain cancer.
The goal of this study is to learn more about the natural history of hereditary antithrombin deficiency and to analyze genetic defects that can cause antithrombin deficiency and correlate with the natural history of the disease.
We are testing the ability of quick tools (bleeding symptom survey and/or ferritin levels) to predict an underlying diagnosis of von Willebrand Disease in teens with HMB.
The purpose of the study is to study the CliniMACS® CD34 Reagent System. It's designed to prevent a serious complication called Graft vs Host Disease (GvHD), which can occur after a type of stem cell transplant known as allogeneic hematopoietic stem cell transplantation (HSCT).
Help researchers study the one-year overall survival of patients undergoing allogeneic HSCT using the T-Cell Receptor (TCR) αβ/CD19+ depleted platform and grafts from alternative donors (MUD, MMUD and haploidentical).
This study will use immune profiling to identify allo-HSCT patients at highest risk for developing HAdV end organ disease.
This study will test the safety and effectiveness of using specific immune cells from related donors to treat adenovirus infections.
The purpose of the study is to collect additional bone marrow and peripheral blood prior to diagnosis of new or recurrent leukemia/lymphoma.
Help researchers study the safety, tolerability, and efficacy of a fixed dose of UD TGFβi NK cells in combination with standard irinotecan, temozolomide, and dinutuximab IV therapy.
Help researchers determine if adding infusions of a type of immune cell called a “natural killer,” or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) is safe and can improve outcomes in people with childhood sarcomas that have relapsed or not responded to prior therapies.
This study will look at how cabozantinib works on more types of pediatric cancers, including neuroblastomas, which are very serious and have few treatment options.
We are testing the ability of quick tools (bleeding symptom survey and/or ferritin levels) to predict an underlying diagnosis of von Willebrand Disease in teens with HMB.
